Procyrion, Inc. Chosen to Present at EuroPCR 2017 in Paris
Heart pump developer Procyrion, Inc. has been selected to participate in the 2017 EuroPCR, which will take place May 16th to 19th at the Palais des Congrès in Paris, France. Chief Scientific Officer Jace Heuring will deliver a presentation and discuss Aortix™.
- Press Releases
High Stakes Quality: Meet Katherine Cox, Quality Magazine's 2017 Quality Professional of the Year
If you have a problem, you want to have Katherine Cox around. Her problem solving skills, team mindset and dedication to quality have earned her Quality Magazine's 2017 Quality Professional of the Year award.
Becker's Hospital Review
Procyrion Named to Becker's List of Disruptive Healthcare Companies to Watch in 2017
Founded in 2005, this Houston-based biotechnology company developed the Aortix system. The Aortix, a minimally invasive catheter-based heart pump, is designed to rest the heart by reducing afterload and improve blood flow to vital organs, according to Procyrion.
Micro Heart Pump Developer, Procyrion, to Test Transcutaneous Energy Transfer Technology from Millar
Medical device firm Procyrion, Inc. announced today that they are working with Millar, Inc. to test Millar’s Transcutaneous Energy Transfer (TET) Technology with Procyrion’s Aortix™ device, the world’s first catheter-deployed circulatory assist device intended for ambulatory use in chronic heart failure patients.
- Press Releases
Procyrion Named as One of Most Innovative Companies in 2016 by PM360
Founded in 2005, Procyrion, Inc. has identified an opportunity in the sweet spot—the time between when the drugs start to fail and a last-resort surgical intervention—to treat millions of NYHA Class III-IVa heart failure patients using a novel and minimally invasive catheter-based heart pump, Aortix.